> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Problem Solvers Caucus Drug Price Principles
- URL: https://www.fdaweb.com/problem-solvers-caucus-drug-price-principles/
- Published: 2019-06-27T12:00:00.000Z
- Updated: 2026-09-15T01:35:15.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5144446

Members of the congressional Problem Solvers Caucus, 23 Democrats and 23 Republicans from both the House and the Senate, have released a list of seven principles for supporting prescription drug pricing legislation. A media [statement](http://www.fdaweb.com/download.php?file=collins%5Fmanchin%5Fpress%5Frelease%5F6-27-19.docx) from Sens. **Susan Collins** (R-ME) and **Joe Manchin** (D-WV) said legislation to address the country’s constantly rising prescription drug prices would also boost access to healthcare nationwide, increase price transparency, and grow competition. The principles are: 

- support access to medications for patients through more transparency, competition, and affordability in the U.S. prescription drug market;
- support price transparency standards that give patients, healthcare providers, and the federal government clear information about drug costs;
- believe drug manufacturers should have to disclose, in a way consumers and providers can understand, the price of treatment for advertised drugs and explanation of prices;
- believe pharmacy benefit managers should have to disclose, in a way consumers and providers can understand, the discounts they receive from drug manufacturers that affect the cost of medications for patients;
- support patent transparency standards that help new drugs come to market as soon as possible;
- support competition among drug manufacturers that ensures continued research and development, makes drugs more affordable, and increases access for patients who need them; and
- believe in enforcement mechanisms that pave the way for new, more affordable drugs if other manufacturers do not comply with transparency standards or engage in anti-competitive behavior.